New hope for Hodgkin's: immune-boosting drug plus chemo shows promise
NCT ID NCT04067037
First seen Feb 01, 2026 · Last updated Jun 19, 2026 · Updated 19 times
Summary
This study tests a new combination treatment for people with advanced classical Hodgkin's lymphoma who have not had treatment before. The drug camrelizumab (which helps the immune system fight cancer) is given together with a standard chemotherapy regimen called AVD. The goal is to see how well the combination works at shrinking or eliminating tumors, and to check for side effects. About 60 adults aged 18 to 75 are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
An Yang Tumor Hospital
Anyang, Henan, 455000, China
-
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China
-
The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
Luoyang, Henan, 471003, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.